We are live on ! Find out more
CG

Column Group Portfolio holdings

AUM $101M
1-Year Est. Return 290.34%
This Fund
S&P 500
This Quarter Est. Return
+24.4%
1 Year Est. Return
+290.34%
3 Year Est. Return
+185.99%
5 Year Est. Return
+29.33%
10 Year Est. Return
–
AUM
$82.8M
AUM Growth
+$1.83M
Cap. Flow
+$5.38M
Cap. Flow %
6.5%
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
1
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
SRZN icon
Surrozen
SRZN
+$5.69M

Top Sells

Rank Stock Value
1
RAPT
RAPT Therapeutics
RAPT
+$304K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRZN icon
1
Surrozen
SRZN
$229M
$41.8M 50.54%
1,851,350
+351,577
+23% +$5.69M
ORIC icon
2
Oric Pharmaceuticals
ORIC
$1.25B
$29M 34.98%
3,540,777
– –
TNYA icon
3
Tenaya Therapeutics
TNYA
$168M
$6.69M 8.08%
9,400,290
– –
RAPT
4
DELISTED
RAPT Therapeutics
RAPT
$5.29M 6.39%
156,270
-9,805
-6% -$304K
RVMD icon
5
Revolution Medicines
RVMD
$40.2B
$3.66K ﹤0.01%
46
– –

Similar funds

ROP
Rule One Partners Moreland, Georgia $101M AUM 6.3% 1-Year Est. Return
PRAG
Portfolio Resources Advisor Group Coral Gables, Florida $101M AUM
XC
XY Capital Central, Hong Kong $101M AUM 1.14% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
VCM
Vines Capital Management Monroe, Louisiana $101M AUM
TCI
Triveni Capital Investments Stamford, Connecticut $101M AUM
RPC
Royal Palms Capital Whitefish, Montana $101M AUM
AWA
Ark Wealth Advisors Yorba Linda, California $101M AUM

Column Group's Q4 2025 Portfolio in Review

As of Q4 2025, Column Group held 5 positions worth $82.8M, up 2.3% from $81M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Column Group deployed $5.38M of net new capital in Q4 2025, adding to 1 existing holding.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was RAPT Therapeutics, an estimated $304K trimmed.

  • Column Group added most to Surrozen in Q4 2025, an estimated $5.69M increase.
  • Column Group's biggest Q4 2025 reduction was RAPT Therapeutics, cutting an estimated $304K.
  • Column Group's ten largest holdings make up 100% of its $82.8M portfolio in Q4 2025.
  • Column Group opened 0 new positions and closed 0 in Q4 2025.
  • Column Group's portfolio value rose 2.3% quarter-over-quarter to $82.8M.

Based on Column Group's 13F filing for Q4 2025, filed 13 Feb 2026.